Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
591.00
-22.00 (-3.59%)
Mar 5, 2026, 1:35 PM CST
288.82%
Market Cap 39.58B
Revenue (ttm) 29.99M
Net Income (ttm) -373.72M
Shares Out 64.57M
EPS (ttm) -6.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 480,070
Average Volume 299,409
Open 617.00
Previous Close 613.00
Day's Range 585.00 - 648.00
52-Week Range 105.50 - 758.00
Beta n/a
RSI 56.25
Earnings Date Mar 13, 2026

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen receptor T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6949
Full Company Profile

Financial Performance

In 2024, Pell Bio-Med Technology's revenue was 19.63 million, an increase of 8.86% compared to the previous year's 18.03 million. Losses were -389.42 million, -2.34% less than in 2023.

Financial Statements

News

There is no news available yet.